Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.186 EUR | -1.17% | -4.35% | -35.86% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.86% | 122M | C- | ||
+5.31% | 70.44B | A | ||
+10.97% | 8.94B | A- | ||
-16.83% | 4.75B | A- | ||
+43.48% | 4.5B | - | ||
+3.20% | 3.85B | B- | ||
-21.36% | 2.34B | C- | ||
-29.67% | 2.2B | - | ||
+8.38% | 1.96B | - | - | |
+3.90% | 1.65B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DBV Stock
- Ratings DBV Technologies